Breakthrough Infections with SARS-CoV-2 Omicron Variant Despite Booster Dose of mRNA Vaccine

Kuhlmann, Constanze; Mayer, Carla Konstanze; Claassen, Mathilda; Maponga, Tongai; Sutherland, Andrew D.; Suliman, Tasnim; Shaw, Megan L.; Preiser, Wolfgang

doi:10.2139/ssrn.3981711

Cited by 41 publications

(33 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, recent reports showed that the efficacy of two doses of BNT162b2 vaccine has dropped from over 90% against the original SARS-CoV-2 strain to approximately 40% and 33% against B.1.1.529 in the United Kingdom 39 and South Africa 40 , respectively. Even a third booster shot may not adequately protect against Omicron infection 39,41 , although the protection against disease still makes it advisable to administer booster vaccinations. Vaccines that elicited lower neutralizing titers 35,42 are expected to fare worse against B.1.1.529.…”

Section: Discussionmentioning

confidence: 99%

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Liu

Iketani

Guo

et al. 2021

Nature

301

485

View full text Add to dashboard Cite

This is a PDF file of a peer-reviewed paper that has been accepted for publication. Although unedited, the content has been subjected to preliminary formatting. Nature is providing this early version of the typeset paper as a service to our authors and readers. The text and figures will undergo copyediting and a proof review before the paper is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

show abstract

Section: Discussionmentioning

confidence: 99%

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Liu

Iketani

Guo

et al. 2021

Nature

301

485

View full text Add to dashboard Cite

show abstract

“…In fact, recent reports showed that the efficacy of two doses of BNT162b2 vaccine has dropped from over 90% against the original SARS-CoV-2 strain to approximately 40% and 33% against B.1.1.529 in the United Kingdom 32 and South Africa 33 , respectively. Even a third booster shot may not adequately protect against Omicron infection 32,34 , but of course it is advisable to do so.…”

Section: Discussionmentioning

confidence: 99%

Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2

Liu

Iketani

Guo

et al. 2021

Preprint

View full text Add to dashboard Cite

The Omicron (B.1.1.529) variant of SARS-CoV-2 was only recently detected in southern Africa, but its subsequent spread has been extensive, both regionally and globally1. It is expected to become dominant in the coming weeks2, probably due to enhanced transmissibility. A striking feature of this variant is the large number of spike mutations3 that pose a threat to the efficacy of current COVID-19 vaccines and antibody therapies4. This concern is amplified by the findings from our study. We found B.1.1.529 to be markedly resistant to neutralization by serum not only from convalescent patients, but also from individuals vaccinated with one of the four widely used COVID-19 vaccines. Even serum from persons vaccinated and boosted with mRNA-based vaccines exhibited substantially diminished neutralizing activity against B.1.1.529. By evaluating a panel of monoclonal antibodies to all known epitope clusters on the spike protein, we noted that the activity of 18 of the 19 antibodies tested were either abolished or impaired, including ones currently authorized or approved for use in patients. In addition, we also identified four new spike mutations (S371L, N440K, G446S, and Q493R) that confer greater antibody resistance to B.1.1.529. The Omicron variant presents a serious threat to many existing COVID-19 vaccines and therapies, compelling the development of new interventions that anticipate the evolutionary trajectory of SARS-CoV-2.

show abstract

“…In contrast to the Beta or Delta VOC, population-wide epidemiological evidence and several studies demonstrated that the Omicron variant is associated with a significant ability to escape humoral immunity [23]. This might explain why even three doses of mRNA vaccines may not be sufficient to prevent infection and symptomatic disease with this VOC [24].…”

Section: Immune Evasionmentioning

confidence: 99%

Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review

Tiecco

Storti

Antoni

et al. 2022

IJMS

View full text Add to dashboard Cite

The Coronavirus disease 2019 (COVID-19) pandemic poses a great threat to global public health. The original wild-type strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has genetically evolved, and several variants of concern (VOC) have emerged. On 26 November 2021, a new variant named Omicron (B.1.1.529) was designated as the fifth VOC, revealing that SARS-CoV-2 has the potential to go beyond the available therapies. The high number of mutations harboured on the spike protein make Omicron highly transmissible, less responsive to several of the currently used drugs, as well as potentially able to escape immune protection elicited by both vaccines and previous infection. We reviewed the latest publication and the most recent available literature on the Omicron variant, enlightening both reasons for concern and high hopes for new therapeutic strategies.

show abstract

Breakthrough Infections with SARS-CoV-2 Omicron Variant Despite Booster Dose of mRNA Vaccine

Cited by 41 publications

References 0 publications

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2

Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review

Contact Info

Product

Resources

About